Amgen Inc. stock (US0311621009): EU approves Imdylltra as shares ease from recent highs

Amgen Inc. shares on Nasdaq trade slightly lower as of early June while the European Commission grants approval for the lung cancer therapy Imdylltra, adding a fresh regulatory milestone to the US biotech group's pipeline story after its strong first-quarter 2026 earnings.

Amgen Inc. shares on the Nasdaq Stock Market, traded under the ticker AMGN, have eased from their recent highs in early June 2026, even as the United States-based biotechnology group secured an important regulatory win in Europe with approval of its lung cancer therapy Imdylltra. According to recent market data, the stock has been fluctuating in the mid-USD 330s, down modestly on the day in some sessions after a strong run earlier this year, leaving the company trading below its 52-week high around USD 390 on the US market, as reported by Business Insider on 06/02/2026. While short-term price moves have been mixed, the fresh decision from the European Commission adds another layer of support to Amgen's strategic push in oncology and reinforces its status as a large-cap constituent of major US equity benchmarks such as the S&P 500.

The latest regulatory milestone came when the European Commission approved Imdylltra (tarlatamab) for the treatment of adult patients with extensive-stage small cell lung cancer who have experienced disease progression on or after platinum-based chemotherapy, as outlined in a press release issued on 06/02/2026. The decision was based on the Phase 3 DeLLphi-304 trial, which demonstrated a 40% reduction in the risk of death with Imdylltra compared to chemotherapy, with a hazard ratio of 0.60 and a median overall survival benefit that underpins Amgen's growing oncology portfolio. The European approval expands the commercial footprint of Imdylltra beyond the United States and highlights how Amgen continues to convert its research and development efforts into marketed products in key global regions. For investors in Germany, Amgen is also accessible via trading venues such as Tradegate and Frankfurt where the shares are quoted in euros alongside the primary US listing, offering an additional route for local participation in the stock.

The stock traded at approximately USD 336 on Nasdaq on recent trading days around 06/02/2026, based on live quote information cited by Business Insider and other market data providers that track AMGN on the US exchange, indicating only modest daily percentage moves. This level leaves Amgen at a discount to its 52-week highs but still significantly above lows seen in the prior year, reflecting how the market is weighing its pipeline progress, integration of recent acquisitions, and the trajectory of key franchises in oncology, immunology, and cardiovascular disease. The US dollar-based pricing on Nasdaq remains the primary reference for international investors, with domestic US institutions typically viewing the shares within the broader healthcare and biotech segment of the S&P 500. In the German context, the euro quotes on platforms like Tradegate loosely track the US price once currency effects are considered, giving retail investors a familiar local-currency handle on the name.

Beyond the immediate stock-price context, trading interest in Amgen has been supported by solid fundamental data. In its most recent reported quarter for the first quarter of 2026, the company posted earnings per share of USD 5.15, beating the consensus estimate of USD 4.77, and reported revenue of USD 8.62 billion, up 5.8% year on year, according to coverage summarized by MarketBeat in an alert dated 06/02/2026. That performance underscored the resilience of Amgen's diversified product portfolio and its ability to grow revenue in the mid-single digits despite pricing pressures and competition in several therapeutic categories. The European approval of Imdylltra arrives against that backdrop of ongoing earnings expansion and underlines how regulatory progress can reinforce the earnings base over the medium term.

As of: 02/06/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Amgen Inc.
• Sector/industry: Biotechnology and biopharmaceuticals
• Headquarters/country: Thousand Oaks, United States
• Core markets: United States, Europe, and other international pharmaceutical markets
• Key revenue drivers: Innovative biologic therapies and medicines in oncology, cardiovascular disease, inflammation, bone health, and other specialty indications
• Home exchange/listing venue: Nasdaq (AMGN)
• Trading currency: USD

Amgen Inc.: core business model

Amgen focuses on discovering, developing, and commercializing human therapeutics, with revenues primarily generated from a portfolio of biologic and targeted medicines across oncology, inflammation, cardiovascular, and other serious disease areas.

Latest quarterly results for Amgen Inc. at a glance

The most recent quarterly snapshot available for Amgen covers the first quarter of 2026, when the company reported earnings per share of USD 5.15 and revenue of USD 8.62 billion, according to a MarketBeat summary referencing the companys earnings release, published on 06/02/2026. That EPS outcome exceeded the consensus forecast of USD 4.77, while the revenue line grew 5.8% from the prior-year quarter, indicating that Amgen was able to deliver both top-line expansion and margin resilience during the period. The performance reflects ongoing demand for key products across its oncology and immunology franchises, as well as contributions from newer launches and recently acquired assets, although detailed segment data for the quarter remain centered on the formal financial tables in the companys regulatory filings.

These quarterly figures are particularly relevant when viewed alongside the European Commissions approval of Imdylltra because they show that Amgen entered this latest regulatory milestone from a position of financial strength. With Q1 2026 revenue already expanding in the mid-single digits, additional geographic approvals for innovative oncology medicines can help sustain or enhance future revenue streams, even as older products face biosimilar competition and pricing dynamics in the United States and abroad. Investors monitoring the stock on Nasdaq and on German trading platforms such as Tradegate can therefore contextualize the early-June 2026 price action against a backdrop of both recent earnings outperformance and incremental regulatory traction in Europe.

Conclusion

The early-June 2026 narrative around Amgen Inc. blends modest share-price consolidation on Nasdaq with a notable regulatory advance in Europe, as the European Commission grants approval for Imdylltra based on Phase 3 data showing a 40% reduction in risk of death versus chemotherapy in extensive-stage small cell lung cancer. That milestone extends the global reach of Amgens oncology pipeline at a time when the company is already delivering mid-single-digit revenue growth and earnings that surpassed consensus expectations in the first quarter of 2026, underscoring that pipeline execution and financial delivery are moving in tandem. While near-term share-price fluctuations will continue to reflect broader market conditions and sector sentiment, the latest approval and the recent earnings beat together frame how the US biotech group is positioning itself in core markets such as the United States and Europe for the coming quarters.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.